The UCLA Anxiety and Depression Research Center has been involved in research designed to implement effective treatments for anxiety disorders within real world settings and in particular in the primary care setting where the majority of individuals with anxiety disorders first present for treatment. We have completed a large, NIMH funded, multi-site study called Collaborative Care for Anxiety and Panic (CCAP) evaluating the efficacy of a brief cognitive behavioral intervention and expert guidelines for psychotropic medications; this treatment was more effective than treatment as usual both in the short term and 12 months later.
In a second NIMH funded, multi-site study called Coordinated Anxiety Learning and Management (CALM) we are currently investigating the effectiveness of a computer-assisted cognitive behavioral therapy program and/or anxiolytic medication for four of the major anxiety disorders presenting in primary care, Generalized Anxiety Disorder, Panic Disorders with or without Agoraphobia, Social Phobia, and Post Traumatic Stress Disorder. The CALM intervention is being compared to Treatment As Usual (TAU). There are 4 study sites across the county (i.e., Los Angeles, San Diego, Seattle, and Little Rock).
More information can be found:
- https://www.clinicaltrials.gov/ct2/show/NCT00347269
- https://nda.nih.gov/edit_collection.html?id=2146
Eligibility Criteria
Participants must be patients at one of two designated primary care clinic sites: Desert Medical Group Oasis IPA in Palm Springs and the High Desert Medical Group in Lancaster. Participants must be English or Spanish speaking, between the ages of 18 and 75, not suffering from severe medical conditions, have a telephone, and plan to remain associated with the designated primary care clinic for the next two years. UPDATE: Enrollment is now complete. Over 1000 participants were enrolled across the 4 study sites.
Screening Procedures
Eligible participants are screened in the clinics and/or referred to the study by their own physicians. After a phone delivered diagnostic evaluation, eligible participants are randomized to either cognitive behavioral therapy and/or expert guidelines for psychotropic medications specifically designed for anxiety disorders, or to treatment as usual.
Treatment Procedures
Participants in the cognitive behavioral therapy and/or medication management treatment receive approximately 8 sessions of treatment with follow-up phone calls for up to one year. Participants assigned to TAU follow procedures determined by their primary care doctor. Four assessments are conducted, the first just after enrollment, and then at 6, 12 and 18 months after enrollment. Assessments involve a battery of self report questionnaires and a diagnostic evaluation, all conducted over the phone.
Fees
There are no fees for any of the assessments or treatment visits. Participants will be paid $50 for each of the first 3 assessments and $75 for the last one.
Study Personnel Contact
For further information contact Project Director, Raphael D. Rose, Ph.D., at (310) 825-9048 or by email. This study is conducted in collaboration with Peter Roy-Byrne, M.D., University of Washington, Seattle, Murray Stein, M.D., UCSD, Greer Sullivan, M.D., University of Arkansas, and Cathy Sherbourne, Ph.D., RAND.
Principal Investigator: Michelle G. Craske, Ph.D. (UCLA site).
NIMH 2 R01 MH58915-05A2